Live Breaking News & Updates on Innovent Announces

Stay updated with breaking news from Innovent announces. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351

China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United States , Hong Kong , Long Wu , Rhui Zhou , Eli Lilly , Adimab Incyte , Innovent Biologics , Sasia Congress , European Society For Medical Oncology , American Association For Cancer Research Annual Meeting , Md Anderson Cancer Center , Guangdong Lung Cancer Institute , National Medical Products Administration , American Society Of Clinical Oncology , China National Medical Products Administration , Incyte Corporation , Prnewswire Innovent Biologics Inc , Innovent Announces , China Has Accepted , Granted Priority Review Designation , New Drug Application , Drug Evaluation , Priority Review , European Society , Medical Oncology , Guangdong Provincial People ,

Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors | Antibodies

Hits: 207
SAN FRANCISCO, CA, USA and SUZHOU, China I July 25, 2021 I Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the first patient has been dosed in a Phase 1 study of IBI321, an anti-PD-1/TIGIT bispecific antibody.
The objective of this open-label, multi-center Phase 1a dose escalation and expansion study is to evaluate the safety, tolerability, potential optimal dosage and preliminary efficacy of IBI321 in patients with advanced malignant tumors whose cancer progressed on standard-of-care treatment. The trial is being conducted in China. ....

United States , Hong Kong , Baohui Han , Adimab Incyte , Inovent Biologics , Xiangdong Cheng , Eli Lilly , Clinical Development Of Innovent , Respiration Department , Treatment Technology Research Center , Md Anderson Cancer Center , I Innovent Biologics Inc , Innovent Announces , First Patient Dosed , Advanced Malignant Tumors , Chinai July , Innovent Biologics , Shanghai Chest Hospital , Cancer Hospital , Chinese Academy , Zhejiang Cancer Hospital , Senior Vice President , Clinical Development , Main Board , Stock Exchange , Hong Kong Limited ,

Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI323 (Anti-LAG-3/PD-L1 Bispecific Antibody) in Patients with Advanced Malignant Tumors | Antibodies

Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI323 (Anti-LAG-3/PD-L1 Bispecific Antibody) in Patients with Advanced Malignant Tumors | Antibodies
pipelinereview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pipelinereview.com Daily Mail and Mail on Sunday newspapers.

United States , Hong Kong , Adimab Incyte , Innovent Bio , Caicun Zhou , Eli Lilly , Cancer Institute Of Tongji University Medical School , Clinical Development Of Innovent , Drug Administration , Md Anderson Cancer Center , I Innovent Biologics Inc , Innovent Announces , First Patient Dosed , Advanced Malignant Tumors , Chinai July , Innovent Biologics , Oncology Department , Shanghai Pulmonary Hospital Affiliated , Tongji University , Cancer Institute , Tongji University Medical School , Senior Vice President , Clinical Development , Main Board , Stock Exchange , Hong Kong Limited ,